literature

HIV mutation literature information.

Use of amplification refractory mutation system PCR assay as a simple and effective tool to detect HIV-1 drug resistance mutations.

PMID: 25788547 2015 Journal of clinical microbiology

Abstract: ARMS-PCR's limits of detection for mutations M184V, T215Y/F, K103N, and Y181C were <75 copies/ml, 143 copies/ml, 143 copies/ml, and 836 copies/ml, respectively.

Abstract: The ARMS-PCR assay was able to detect M184V, T215Y/F, K103N, and Y181C mutations with sensitivities of 96.8%, 85.7%, 91.3%, and 70%, respectively, and specificities of 90.6%, 95%, 100%, 96.9%, respectively, compared with data on sequencing.

Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.

PMID: 25754408 2015 Journal of medical virology

Result: A wide range of mutations conferring multi-NRTI resistance were also observed, including M41L (n = 7, 10%), A62V (n = 15, 22%), D67N (n = 10, 15%), K70R (n = 10, 15%), V75I (n = 2, 3%), F77L (n = 1, 1%), Y115F (n = 6, 9%), F116Y (n = 1, 1%), Q151M (n = 1, 1%), L210W (n = 3, 4%), T215Y/F (n = 7, 10%) and (n = 5, 7%), and K219Q/E (n = 4, 6%) and (n = 7, 10%).

Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

PMID: 25711326 2015 HIV medicine

Abstract: The most frequent TDR mutations observed were M41L, D67N/G/E, T215F/Y/I/S/C/D/E/V/N, 219Q/E/N/R, K103N/S, and G190A/S/E in reverse transcriptase, and M46I/L and L90M in protease.

Method: To obtain a standard interpretation across tests, HIV-1 transmitted drug resistance was defined according to the World Health Organization (WHO) 2009 surveillance list, with the addition of T215N (a revertant of T215F/Y omitted from the list) and E138K (a nonpolymorphic rilpivirine-associated muta

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses.

PMID: 25680310 2015 Clinical microbiology and infection

Abstract: The most common TC-DRM present in >=50% of them were D67NME, T215FVY, M41L and K103N (retrotranscriptase) and L90M (protease).

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

PMID: 25344810 2015 The Journal of antimicrobial chemotherapy

Abstract: Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P=0.0455) and T215Y (P=0.0455).

Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.

PMID: 25575025 2014 Retrovirology

Abstract: The majority of site-directed mutations (M46I/M46L in protease and M41L, M41L + T215Y and K103N in RT) decreased viral replicative capacity; only protease mutation L90M did not hamper viral replication.

Result: The reduction in RC of the M41L, M41L + T215Y and K103N variants was comparable to each other, and to controls HIV

Discussion: Of the investigated site-directed mutant viruses, T215Y is known to evolve to atypical or partial revertant amino acids.

[The efficacy of antiviral therapy and drug resistance analysis among HIV/AIDS patients with heroin addiction in Guangxi Zhuang Autonomous Region].

PMID: 25573121 2014 Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Abstract: Among the patients who received antiviral treatment, the mutation frequency of M184V/I, T215Y/F, L210W and T69N/S in heroin abuser group were significantly higher than that in never using drug group (14.9% (11/74) vs 4.4% (3/68), 12.2% (9/74) vs 1.5% (1/68), 12.2% (9/74) vs 1.5% (1/68) and 10.8% (8/74) vs 1.5% (1/68) respectively) (P < 0.05).

HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya.

PMID: 25487529 2014 BMC research notes

Abstract: Eight (8) patients had NRTI resistance mutations with NAMS M184V (54.2%) and K65R (8.4%) mutations being the highest followed by TAMs T215Y and K70R (12.5%).

Abstract: However, for NRTI two patients had TAM T215Y.

Result: However four patients had diverse drug mutations combinations of K103N and V108IV (n = 1); Y184V, G190A and T215Y (n = 1); K103N, M184V and T215Y (n = 1); and A98G,

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles.

PMID: 25397502 2014 Journal of the International AIDS Society

Abstract: Three patients taking PI-based regimens developed NRTI mutations (M184V, M184I, T215Y).

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.

PMID: 25397500 2014 Journal of the International AIDS Society

Table: T215Y